Innate Immune Cell Therapy with Stem Cell Transplants

Project: Research project

Description

DESCRIPTION (provided by applicant): Approximately 80% of patients with chemo-resistant intermediate grade non-Hodgkin's lymphoma (NHL) will relapse following high-dose chemotherapy with autologous stem cell transplantation (ASCT). Our ability to further intensify chemotherapy to improve the outcome of ASCT has reached a plateau, necessitating a need for development of novel therapeutic strategies. Rituximab is a chimeric monoclonal antibody directed against CD20, found on most B-cell NHL. As a single agent, rituximab is modestly effective with
StatusFinished
Effective start/end date9/30/029/29/05

Funding

  • National Institutes of Health: $328,188.00
  • National Institutes of Health: $328,188.00

Fingerprint

Cell- and Tissue-Based Therapy
Non-Hodgkin's Lymphoma
Stem Cells
Stem Cell Transplantation
Transplants
Drug Therapy
B-Cell Lymphoma
Monoclonal Antibodies
Recurrence
Rituximab
Therapeutics

ASJC

  • Medicine(all)